ISIS 2922 antisense intravitreal data

ISIP (Carlsbad, Calif.) reported on Phase I/II data analysis by independent, masked review of fundoscopic photographs. At 330 µg doses, the ISIS 2922 antisense agent was effective in halting progression of the retinal infection, with median time to progression of 61.5 days, compared to historic median time of 35 days with ganciclovir therapy.

Out of 18 patients (22 eyes treated), 12 patients (18 eyes) had their infection controlled with no progression during the study. The remaining patients received insufficient doses to be evaluated. The patients all had progressed two or more times while on intravenous ganciclovir or foscarnet, or had become intolerant of these drugs. ...